Key Takeaways
- In the STEP Young trial, weekly semaglutide cut BMI by 13.5% at week 68 in children aged 6–11, versus a 2.7% rise on placebo.
- 38% of children on the drug were no longer classed as having obesity, versus 2% on placebo — but 70% experienced vomiting.
- The benefit faded over time and after stopping, and the drug is not approved for children under 12.
Should a 7-year-old be on a weight-loss injection?
It is a question paediatricians have been dreading and expecting in equal measure. This week, the New England Journal of Medicine published the first major trial of a GLP-1 drug in young children — and the results are hard to wave away. In the STEP Young trial, 167 children aged 6 to 11 with obesity were given weekly semaglutide injections — the drug sold as Wegovy — or a placebo, alongside lifestyle counselling, for just over two years.
At the trial's main checkpoint, week 68, the difference was stark. BMI in the semaglutide group had fallen 13.5%, while BMI in the placebo group had risen 2.7%. And 38% of the children on the drug were no longer classed as having obesity at all, compared with just 2% on placebo.
The side effects were not minor
The drug's power came with a rough ride. Gastrointestinal problems were the most common side effects, and in the trial's full safety data, 70% of children on semaglutide vomited, versus 29% on placebo; diarrhea and nausea were also far more common. Most episodes were mild to moderate and clustered in the first months as the dose climbed, and only one child stopped treatment because of them — but a drug that makes seven in ten children vomit is not a casual prescription.
The benefit also faded over time. By week 104, the average BMI reduction had shrunk from 13.5% to 9.4%, and BMI rose again once treatment stopped — the same pattern seen in adults, suggesting the drug manages obesity rather than curing it.
What this does and does not change
Two honest caveats. First, the trial was funded by Novo Nordisk, which makes Wegovy, and several authors are its employees. Second, semaglutide is approved for obesity only in people 12 and older — no weight-loss drug is approved for children under 12, and this single trial, however strong, does not by itself change that. Regulators will now weigh a real benefit against real side effects in children whose bodies are still growing.
Health note: This trial involved children with obesity under close medical supervision. GLP-1 drugs are prescription medicines with significant side effects, and they are not approved for weight loss in children under 12. Families concerned about a child's weight should start with their family doctor or paediatrician, not with medication marketed online.
The Twikup Take
Childhood obesity has resisted every gentle intervention medicine has tried, and a 13.5% BMI drop is not a small thing. But a weekly injection, started at age seven and likely needed for years, with a 70% vomiting rate, is a serious medical commitment — the debate this trial starts will be as much about values as about data.
Image: Illustrative image.
